Top Insights
Health
globalreutersOctober 29, 20241 Mins read
AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition
globalreutersOctober 29, 20241 Mins read 
Aliada brings AbbVie an early clinical Alzheimer’s disease drug candidate as well as the platform technology that produced it. Aliada licensed its brain delivery technology from Johnson & Johnson.
The post AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition appeared first on MedCity News.
Related Articles
Heat-related illnesses are preventable; here’s how
By PHIYEN NGUYEN & KRISTINA CARVALHO As we enjoy the crisp air...
WTW: There’s A Disconnect Between Employers and Employees on Wellbeing Programs
Employers are prioritizing mental wellbeing programs, but employees say they need financial...
Best hospital for Congenital Hip Dislocation Treatment
Developmental dysplasia of the hip, also known as congenital hip dislocation, is...
A Retrospective Claims Analysis of the Rate of Complications in Patients Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria
That is the title of my recent paper with co-authors Denise Clayton,...
Leave a comment